Abstract
| Original language | English |
|---|---|
| Journal | European Journal of Immunology |
| Volume | 46 |
| Issue number | Suppl. 1 |
| Pages (from-to) | 154-154 |
| ISSN | 0014-2980 |
| Publication status | Published - 2016 |
| Event | ICI 2016 International Congress of Immunology - Melbourne, Australia Duration: 21 Aug 2016 → 26 Aug 2016 |
Conference
| Conference | ICI 2016 International Congress of Immunology |
|---|---|
| Country | Australia |
| City | Melbourne |
| Period | 21/08/2016 → 26/08/2016 |
Cite this
}
TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut. / Kadivar, M.; Petersson, J.; Bekiaris, Vasileios; Marsal, J.; Svensson, L.
In: European Journal of Immunology, Vol. 46, No. Suppl. 1, 2016, p. 154-154.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
TY - ABST
T1 - TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut
AU - Kadivar, M.
AU - Petersson, J.
AU - Bekiaris, Vasileios
AU - Marsal, J.
AU - Svensson, L.
PY - 2016
Y1 - 2016
N2 - γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.
AB - γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.
M3 - Conference abstract in journal
VL - 46
SP - 154
EP - 154
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - Suppl. 1
ER -